SureTrader SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Oxis International Inc. (OXIS)

OXIS RSS Feed
Add OXIS Price Alert      Hide Sticky   Hide Intro
Moderator: Porteño, 136, CashBowski
Search This Board:
Last Post: 9/30/2016 10:37:45 AM - Followers: 141 - Board type: Free - Posts Today: 0


 

Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!

Overview

Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.


Management



 

Company Website
http://oxis.com

 


Corporate Overview - Presentation
Fall 2015
Click the link: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10968247


 




 





 

 

OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet

 

SCIENTIFIC ADVISORY BOARD

XIANG-QUN (SEAN) XIE, M.D., Ph.D., EMBA

Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.

JAMES J. MULE, Ph.D.

Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.

STEPHEN M. CHANG, Ph.D.

Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.

LISA A. HAILE, Ph.D.

Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.

 

Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.

 Chart

Stock Information:


 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OXIS
Current Price
Volume:
Bid Ask Day's Range
SureTrader
OXIS News: Securities Registration Statement (s-1/a) 08/25/2016 06:01:53 AM
OXIS News: Securities Registration Statement (s-1) 08/24/2016 06:01:43 AM
OXIS News: Quarterly Report (10-q) 08/10/2016 04:08:22 PM
OXIS News: Current Report Filing (8-k) 08/09/2016 06:10:58 AM
OXIS News: Medical Marijuana Product Advancements Propelling Cannabis Industry As Revenues From Sales Forecasted For Exponential Growth 07/20/2016 08:30:00 AM
PostSubject
#8101  Sticky Note NEWS!! LOS ANGELES, CA / ACCESSWIRE / July GreenDoesCure420 07/25/16 09:28:42 AM
#7727  Sticky Note $OXIS - OXS-1550 (DT2219) SUCCESS 136 03/29/16 09:15:29 PM
#8231   psssst biei animaljive 09/30/16 10:37:45 AM
#8230   The downward pressure continues... CashBowski 09/27/16 06:48:35 PM
#8229   Choked on this one heaviestD 09/22/16 11:28:33 AM
#8228   What Milestones? vlay 09/21/16 10:44:00 AM
#8227   Milestones approaching $OXIS 136 09/21/16 12:29:26 AM
#8226   Someone cut these guys a check for a Dip66 09/19/16 02:16:00 PM
#8225   Anthony/Steve - You guys get funding yet?? Let's Dip66 09/16/16 11:27:04 AM
#8224   The dumping comes in waves. The chart tells Halks1122 09/12/16 07:50:04 PM
#8223   Many good things happening... patience. Gibba 09/12/16 11:38:14 AM
#8222   It's a good thing that its been somewhat CashBowski 09/12/16 07:40:17 AM
#8220   Oxis Biotech to Discuss its Cancer-Fighting Platforms at TPX 09/08/16 09:59:05 AM
#8219   OXIS Oxis Biotech's TriKE Cancer-Fighting Technology Receives Key TPX 08/29/16 10:02:41 AM
#8218   150 mil authorized and 28 mil OS as CashBowski 08/25/16 01:43:05 PM
#8217   Does anyone know, or can it be determined Gibba 08/25/16 12:16:05 PM
#8216   I seriously doubt it. They will likely need CashBowski 08/25/16 06:17:04 AM
#8215   Um, no. Rapture2020 08/25/16 03:29:53 AM
#8214   Could this open the door to institutional ownership Gibba 08/24/16 03:05:15 PM
#8213   Another public offering of common stock and related CashBowski 08/24/16 02:50:47 PM
#8212   Any thoughts on today's news? Gibba 08/24/16 12:16:25 PM
#8211   Do you remember that part of 10K ? M163648 08/19/16 12:26:07 PM
#8210   Looks now to be a day traders paradise. Gibba 08/17/16 11:21:40 AM
#8209   It was at $3.00+ end of February and Gibba 08/17/16 01:08:32 AM
#8208   And exactly when was this at $3.00? Rapture2020 08/16/16 10:36:19 PM
#8207   Would be nice to see this back at Dip66 08/16/16 11:53:50 AM
#8206   OXIS Oxis Biotech Scientific Advisory Board Member to TPX 08/16/16 07:39:42 AM
#8205   Keep momentum going? Lol. Rapture2020 08/16/16 06:51:14 AM
#8204   I suspect we will get some good news Gibba 08/15/16 09:36:57 PM
#8203   Good day today, probably a bounce off earnings. CashBowski 08/15/16 07:18:16 PM
#8202   10q was good. $OXIS is a solid investment. Gibba 08/15/16 11:39:45 AM
#8201   OXIS on the move. These guys onto something Dip66 08/15/16 10:51:58 AM
#8200   OXIS is starting the Monday morning off RIGHT! 2kimberly 08/15/16 10:08:01 AM
#8199   I doubt this will help ChillinCharlie 08/11/16 09:19:57 AM
#8198   Any comments on 10Q? Gibba 08/10/16 04:45:40 PM
#8197   Lol. Death by a thousand paper cuts. Pre Rapture2020 08/10/16 02:18:34 PM
#8196   MCET used to do the same thing. simon wagstaff 08/10/16 10:48:03 AM
#8195   Maybe, but I believe we will hit .40 Gibba 08/09/16 05:29:05 PM
#8194   I think you're trading with emotion rather than Halks1122 08/09/16 04:57:33 PM
#8193   If anyone followed ATTBF a couple of years FatFreddysCat 08/09/16 01:29:51 PM
#8192   We should see .40 soon based on today's Gibba 08/09/16 11:23:47 AM
#8191   The dilution here is a daily struggle as CashBowski 08/09/16 07:04:55 AM
#8190   Had a dream that OXIS was bought out Gibba 08/08/16 02:57:09 PM
#8189   OXIS is nothing like MCET? simon wagstaff 08/04/16 09:05:01 AM
#8188   $.0006 pre-split????? WAFJ. This time last year Rapture2020 08/03/16 09:56:12 PM
#8187   This will probably be sub-penny by Labor day m931a1 08/02/16 06:24:26 PM
#8186   "news this week" animaljive 08/02/16 03:20:02 PM
#8184   there's no catalysts in the near future to animaljive 08/02/16 03:16:01 PM
#8183   dude, sell. It was hard for me too, djmurdock 08/02/16 02:59:25 PM
#8182   Im down 50% as well. My brain keeps ChillinCharlie 08/02/16 02:56:19 PM
#8181   RIP OXIS got out with a hefty loss djmurdock 08/02/16 02:24:25 PM
#8180   Too bad that OXS-1550 is a bi-specific antibody simon wagstaff 08/01/16 09:14:35 AM
PostSubject